@entity205 therapy for Henoch-Sch  nlein @entity1310 with @entity1985 -range XXXX .

@entity1 @entity644 @entity1310 @entity230 @entity205 @entity1985 @entity454
To evaluate the therapeutic role of @entity205 (CyA) for the treatment of Henoch-Sch  nlein @entity1310 (HSN), 29 @entity1 (18 @entity1 , 11 @entity1 ) with @entity1985 -range @entity644 were analyzed retrospectively. Mean age was 8.6  years (range 2.0-15.5  years) at diagnosis of Henoch-Sch  nlein purpura (HSP). All @entity1 had developed the @entity1985 -range @entity644 at a mean interval of 4.4  months (range 0-50.7  months) after the diagnosis of HSP. Mean duration of CyA treatment was 12.3  months (range 2.6-55.0  months). Mean follow-up times were 3.7  years (range 1.2-12.9  years) from the beginning of the CyA treatment. @entity230 were tapered off and stopped gradually after initiation of CyA. All @entity1 responded to the CyA treatment within a mean of 1.8  months (range 1  week to 3.5  months). Twenty-three @entity1 achieved stable remission with mean follow-up duration of 3.2  years and 6 @entity1 seemed to become CyA-dependent, since they developed @entity644 when the treatment was stopped. Renal function was preserved in all @entity1 but one who developed @entity454 after poor compliance with CyA. We concluded that CyA treatment for HSN showing @entity1985 -range @entity644 is very effective and a safe method, although some @entity1 become CyA-dependent.
